Evaluating Reboxetine and Methylphenidate for Attention, Sensory, and Emotional Challenges in Adults with PTSD
Led by University of Haifa · Updated on 2026-08-11
53
Participants Needed
3
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying adults aged 20 to 60 with Posttraumatic Stress Disorder PTSD to understand attentional, sensory, and emotional difficulties linked to the condition. The study evaluates how attention, emotional regulation, and sensory processing relate in PTSD patients, comparing them to healthy controls. It also investigates the effects of the drugs reboxetine and methylphenidate on these symptoms using a randomized, double-blind controlled trial.
Participants with PTSD will be randomly assigned to receive either active treatment with reboxetine and methylphenidate or a placebo. Reboxetine is taken daily starting at 2 mg for three days, then increased to 4 mg for 26 days. On day 22, methylphenidate or placebo 10 mg is administered twice daily for four days under clinic observation. The placebo group follows the same medication schedule without active drugs.
Throughout the study, participants undergo various assessments including brain activity measurements with functional near-infrared spectroscopy and electroencephalography, attention tests, sensory and executive function questionnaires, and quality of life surveys. The main outcome compares PTSD symptom changes before and after treatment using the Clinician-Administered PTSD Scale. Safety is monitored during medication dosing, with the study lasting approximately 26 days for each participant.
CONDITIONS
Brief Title
Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD
Research Team
A
Avi Avital, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Diagnosed with PTSD according to DSM-IV or DSM-5 criteria
Receiving current treatment at outpatient clinics
Aged between 20 and 60 years
PTSD diagnosis made at least one month before joining
No current re-exposure to traumatic events
Psychotropic medications must be at a stable dose for at least one month
You will not qualify if you...
Having a major psychiatric disorder such as psychotic disorder, bipolar disorder, borderline personality disorder, or active suicidal thoughts
Diagnosis of ADHD
Severe systemic illness limiting normal activity (e.g., autoimmune disease, AIDS, renal failure)
Cardiovascular conditions like hypertension, AV block, bradycardia, or conduction disorders
Life-threatening diseases such as heart attack, respiratory failure, or cancer
Nervous system impairments including multiple sclerosis, Alzheimer's, Parkinson's, epilepsy, or stroke
Previous or current severe traumatic brain injury
Glaucoma
Hearing impairment
Pregnancy or breastfeeding
Active substance dependency including medical cannabis use
Steroid medication use within two months before the study
Use of medications affecting the central nervous system
Incomplete participation in all research steps
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 26 days
Participants receive either reboxetine daily for 26 days starting at a low dose, with methylphenidate or placebo added on day 22 for four days under clinic observation.
Clinic visits on day 1, day 21, day 22 (with 2-hour observation), and day 26
Follow-up Assessments
Duration - Throughout the 26-day study period
Participants complete various assessments including brain activity tests, attention and sensory questionnaires, and quality of life surveys at multiple points during and after treatment.
Assessments on day 1, day 21, and day 26
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Brain Stimulation to Reduce Arousal in Adults with PTSD
Using Intraparietal Sulcus Continuous Theta Burst Stimulation and Extinction Training
Testing Personalized vs Standardized Emotion Regulation Skills
for Improving Emotional Health and Reducing Negative Feelings
Evaluating a Web-Based Moral Elevation Program to Improve PTSD Symptoms, Social Functioning, and Quality of Life in Veterans
Personalized and Adaptive Treatment Strategies for Veterans with PTSD
Using Sequenced Cognitive Processing and Prolonged Exposure Therapies
Research on Alcohol Misuse, PTSD, and Intimate Partner Violence in Couples Using Laboratory and Real-World Methods
Art Therapy to Improve Emotional Expression and Regulation in Military Members With Posttraumatic Stress Symptoms
Study of Electroretinogram ERG Changes After a Single Dose of Sertraline in Veterans with PTSD to Explore Biomarkers for SSRI Response
Study of Reminder-Focused Positive Psychiatry for Adolescents Aged 11 to 15
with Posttraumatic Stress Disorder PTSD
Comparing Brief Behavioral Treatment for Insomnia to Progressive Muscle Relaxation in Veterans with PTSD and Insomnia
Pilot Study of CIH Stepped Care Compared to Usual Treatment for Adults with Chronic Pain and PTSD
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury.